A study in _NEJM AI_ validates the Sepsis ImmunoScore™ as an accurate diagnostic tool for sepsis and predictor of adverse outcomes.

Aquablation shows a significant decrease in IPSS scores by approximately 15 points after 5 years, regardless of prostate size, indicating sustained symptom relief.

The European Union prioritizes a "conditional authorization" for COVID-19 vaccines, emphasizing thorough data checks and manufacturer liability.

Next-generation sequencing (NGS) is crucial for personalizing treatment decisions in hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, identifying actionable mutations like PIK3CA, AKT, and P10.

Pooled analysis of Phase II/III data reveals that imetelstat provides consistent clinical benefits in patients with myelodysplastic syndromes (MDS).

Neurologist Matthew Schrag highlights the increasing prevalence of research misconduct in Alzheimer's disease studies, which he believes has slowed the development of effective treatments.

Dewpoint Therapeutics and Mitsubishi Tanabe Pharma have entered a collaboration to develop a novel ALS drug, potentially worth up to $480 million.

Tirzepatide (Zepbound) achieved a 20.2% mean weight loss, significantly outperforming semaglutide (Wegovy) at 13.7% over 72 weeks in adults with obesity or overweight conditions.

Can-Fite BioPharma's Namodenoson demonstrates liver-protective effects alongside its anti-cancer activity in hepatocellular carcinoma (HCC).

Analysis of the IMvigor011 study reveals that patients with high-risk muscle-invasive bladder cancer (MIBC) who maintain circulating tumor DNA-negative (ctDNA-) status post-cystectomy show favorable clinical outcomes.

NS Pharma's NS-050/NCNP-03, an antisense oligonucleotide, has been granted rare pediatric disease designation by the FDA for Duchenne muscular dystrophy (DMD) treatment.

Everest Medicines' EVER001 demonstrated an 81.8% overall clinical remission rate in the low-dose cohort and 85.7% in the high-dose cohort for pMN patients.

UroGen Pharma's UGN-102 shows an 82.3% duration of response at 12 months in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC).

The FDA has updated the labeling for Heplisav-B to include human data indicating no increased risk of major birth defects or miscarriage.

The NRG Oncology/Alliance LU005 trial found that adding atezolizumab to standard chemoradiotherapy (CRT) did not significantly improve overall survival in patients with limited-stage small-cell lung cancer (LS-SCLC).

The Phase III PADMA trial demonstrated that endocrine therapy plus palbociclib significantly improves time to treatment failure compared to mono-chemotherapy in HER2-negative/HR-positive metastatic breast cancer.

The United Kingdom has granted emergency authorization for the Pfizer-BioNTech COVID-19 vaccine, making it the first country in the world to approve its use.

Nemtabrutinib demonstrates encouraging efficacy in patients with relapsed or refractory follicular lymphoma, according to findings from the BELLWAVE-003 phase 2 trial.

A real-world study evaluating tafasitamab in US patients with relapsed/refractory DLBCL showed a progression-free survival of 11.3 months.

Pembrolizumab demonstrates efficacy in children, adolescents, and young adults with low-risk classic Hodgkin lymphoma showing slow early response to frontline chemotherapy.